Eli Lilly and Company (LLY) — closed signal from May 28, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 26, 2026.
Predicted vs. what happened
LLY price · publication thesis → realized outcomesplit-adjusted
$1,060.00 – $1,110.00Entry zone — fair-value band
$1,112.23Published — price the day we called it
$1,234.57Target — the price the thesis aimed for
$1,292.65Peak — highest point inside the window, not a realized return
$1,189.41Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 32 days.
Peak price
$1,292.65
peak on August 19, 2026 — not a realized returnPeak gain
+16.2%
peak, from the publication priceWindow close
$1,189.41
end-of-window price, context onlyDays to target
32
Window
May 28, 2026 – August 26, 2026
The thesis — published May 28, 2026
Predicted growth
+11%
over the measurement windowTarget price
$1,234.57
the price the thesis aimed forEntry zone
$1,060.00 – $1,110.00
the fair-value band we waited forPrice at publication
$1,112.23
published May 28, 2026Confidence
70%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Eli Lilly is a top healthcare growth company because its weight-loss medicines are in high demand, the drug pipeline and recent buys expand its business, and execution and profits are strong. After a powerful run, the short-term view is cautious: the position looks best as quality exposure on pullbacks rather than expecting fresh rapid gains.
Primary drivers
- Market leader in obesity drugs driving big sales growth
- New drugs and deals widen the company's product lineup
- Positive media and analyst attention supports momentum
- Strong profits help justify growth after recent gains
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.